You are in:Home/Publications/Expression of NCF4 rs1883112 polymorphism and risk of developing Acute Lymphoblastic Leukemia in Egyptian children

Dr. Maha Mohamed Tahir Rashwan :: Publications:

Title:
Expression of NCF4 rs1883112 polymorphism and risk of developing Acute Lymphoblastic Leukemia in Egyptian children
Authors: Amira M. N. Abdelrahman, 1Adel Marzouk Agha, 1Maha M. T. Rashwan, 2 Samar Mahmoud Elbahy, 1Amr Fathy Mohamed Gad, 1Walid Abdellatif Abdelhalim
Year: 2025
Keywords: Not Available
Journal: Not Available
Volume: Not Available
Issue: Not Available
Pages: Not Available
Publisher: Not Available
Local/International: International
Paper Link: Not Available
Full paper Maha Mohamed Tahir Rashwan_8.pdf
Supplementary materials Not Available
Abstract:

Background: Acute lymphoblastic leukemia (ALL) is the most prevalent pediatric malignancy. It has been linked to different genetic variations, including those that impact the generation of reactive oxygen species. Neutrophil cytosolic factor (NCF4) single nucleotide polymorphism (SNP) rs1883112 is one of the implicated genes that may affect susceptibility to ALL. Aim of the study: to evaluate the association between NCF4 rs1883112 and susceptibility to develop ALL in Egyptian children and its correlation to clinical variables, laboratory parameters, and patient outcomes. Patients and methods: This comparative case-control study was conducted on 100 children less than 18 years old who were newly diagnosed with ALL, and 100 healthy controls matched in age and sex. Bone marrow aspiration was carried out principally to permit cytological assessment, immunophenotyping, cytogenetics, molecular genetics, and other specialized investigations. A molecular study on peripheral blood for the detection of NCF4 rs1883112 polymorphism by real-time polymerase chain reaction (RT-PCR) was carried out. Results: The NCF4 rs1883112 polymorphism showed a protective effect against ALL susceptibility, with the GA and AA genotypes, dominant model, and A allele showing a lower frequency in ALL patients compared to controls (p= 0.001, 0.015, 0.001, and 0.009, respectively). AA genotype was significantly associated with a higher frequency of t(12;21), and those achieved complete remission. There was no significant association between NCF4 (rs1883112) genotypes and other cytogenetics or immunophenotyping. The NCF4 rs1883112 dominant genotype hazard ratio was 0.15 for overall survival and 0.24 for disease-free survival by univariate analysis; this remained significant by multivariate analysis, suggesting that the GA/AA genotype was significantly associated with a lower risk of mortality and disease relapse. Conclusion: It is suggested that NCF4 rs1883112 (GA/AA genotype) has a significant protective effect against susceptibility to ALL development, which is associated with favorable outcomes regarding overall survival and diseasefree survival

Google ScholarAcdemia.eduResearch GateLinkedinFacebookTwitterGoogle PlusYoutubeWordpressInstagramMendeleyZoteroEvernoteORCIDScopus